Live Breaking News & Updates on நடாலி மாலை கோலின்ஸ்
Stay updated with breaking news from நடாலி மாலை கோலின்ஸ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
DGAP-News: Newron Pharmaceuticals S.p.A. / Key word(s): Study results 01.04.2021 / 07:00 Newron announces results of explanatory studies with evenamide in healthy volunteers and patients with schizophrenia Primary objective of safety of evenamide met on all safety variables for study 010 in healthy volunteers and study 008 in patients with schizophrenia Additional safety and efficacy study 008A in therapeutic dose (30 mg BID) to start in April 2021 Milan, Italy and Morristown, NJ, USA, April 1, 2021 - Newron Pharmaceuticals S.p.A. ( Newron ) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced initial results from two short-term explanatory studies in evenamide: study 010 in healthy volunteers and study 008 in patients with schizophrenia. ....
Newron announces results of explanatory studies with evenamide in healthy volunteers and patients with schizophrenia Newron Pharmaceuticals SpA / Key word(s): Miscellaneous 01-Apr-2021 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Primary objective of safety of evenamide met on all safety variables for study 010 in healthy volunteers and study 008 in patients with schizophrenia Additional safety and efficacy study 008A in therapeutic dose (30 mg BID) to start in April 2021 Milan, Italy and Morristown, NJ, USA, April 1, 2021 - Newron Pharmaceuticals S.p.A. ( Newron ) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced initial results from two short-term explanatory studies in evenamide: study 010 ....
Newron Pharmaceuticals: Newron Announces Results of Explanatory Studies With Evenamide in Healthy Volunteers and Patients With Schizophrenia Additional safety and efficacy study 008A in therapeutic dose (30 mg BID) to start in April 2021 Newron Pharmaceuticals S.p.A. ( Newron ) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced initial results from two short-term explanatory studies in evenamide: study 010 in healthy volunteers and study 008 in patients with schizophrenia. Results from study 010, a four-week, single dose, cross-over Thorough QT (TQT) study in 56 healthy volunteers, designed to evaluate the effects of evenamide (30 mg and 60 mg) compared with placebo and moxifloxacin 400 mg on the QT segment specifically, and on the electrocardiogram (ECG) generally, was requested by the US Food and Drug Administration (FDA) and unde ....
Newron announces 2020 financial results and provides outlook for 2021 DGAP-News: Newron Pharmaceuticals S.p.A. / Key word(s): Annual Report 16.03.2021 / 07:00 Newron announces 2020 financial results and provides outlook for 2021 Milan, Italy, March 16, 2021 - Newron Pharmaceuticals S.p.A. ( Newron ) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the year ended December 31, 2020, and provided an outlook for 2021. Highlights 2020: Evenamide (Schizophrenia) All evenamide pre-clinical studies requested by the US Food and Drug Administration (FDA) have been completed with no toxicity concerns identified ....